Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential

Antiviral Res. 2020 Aug:180:104824. doi: 10.1016/j.antiviral.2020.104824. Epub 2020 May 22.

Abstract

Hepatitis B virus (HBV) infection remains a major public health concern worldwide with about 257 million individuals chronically infected. Current therapies can effectively control HBV replication and slow down disease progress, but cannot cure HBV infection. Upon infection, HBV establishes a pool of covalently closed circular DNA (cccDNA) in the nucleus of infected hepatocytes. The cccDNA exists as a minichromosome and resists to antivirals, thus a therapeutic eradication of cccDNA from the infected cells remains unattainable. In this review, we summarize the state of knowledge on the mechanisms underlying cccDNA formation and regulation, and discuss the possible strategies that may contribute to the eradication of HBV through targeting cccDNA.

Keywords: Drug target; HBV cccDNA minichromosome; HBV cure; Host-virus interaction; Transcriptional regulation; cccDNA eradication.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antiviral Agents / therapeutic use
  • Clinical Trials as Topic
  • DNA, Circular / genetics*
  • DNA, Viral / genetics*
  • Gene Expression Regulation, Viral*
  • Hepatitis B / therapy
  • Hepatitis B virus / genetics*
  • Hepatitis B, Chronic / therapy
  • Hepatocytes / virology
  • Humans
  • Virus Replication

Substances

  • Antiviral Agents
  • DNA, Circular
  • DNA, Viral